Comerica Bank Sells 7,825 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Comerica Bank has reduced its stake in Thermo Fisher Scientific Inc. by 7.1%, now owning 103,031 shares valued at approximately $51.27 million.
• Several hedge funds have increased their investments in Thermo Fisher, with Brighton Jones LLC leading by boosting its stake by 28.9%.
• Barclays and UBS Group have raised their price targets for Thermo Fisher Scientific shares, indicating a stable outlook with a consensus rating of "Moderate Buy."

Comerica Bank cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 7.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 103,031 shares of the medical research company's stock after selling 7,825 shares during the quarter. Comerica Bank's holdings in Thermo Fisher Scientific were worth $51,268,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in TMO. Bernard Wealth Management Corp. bought a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $25,000. Ameriflex Group Inc. bought a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $30,000. Keystone Global Partners LLC bought a new position in Thermo Fisher Scientific in the first quarter valued at approximately $31,000. IMA Advisory Services Inc. bought a new position in Thermo Fisher Scientific in the first quarter valued at approximately $35,000. Finally, Navigoe LLC bought a new position in Thermo Fisher Scientific in the fourth quarter valued at approximately $37,000. 89.23% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares of the company's stock, valued at $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 28,896 shares of company stock valued at $13,603,438 in the last three months. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Trading Down 0.0%

Shares of NYSE:TMO traded down $0.01 during mid-day trading on Wednesday, reaching $488.47. 1,294,754 shares of the company's stock were exchanged, compared to its average volume of 2,075,498. The firm has a market capitalization of $184.45 billion, a price-to-earnings ratio of 28.25, a PEG ratio of 2.61 and a beta of 0.74. The business's fifty day moving average price is $446.71 and its 200-day moving average price is $455.47. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the previous year, the business earned $5.37 earnings per share. Thermo Fisher Scientific's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on TMO. William Blair began coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an "outperform" rating on the stock. HSBC restated a "hold" rating and issued a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Argus cut their target price on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research report on Tuesday, April 29th. Finally, UBS Group raised their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $593.00.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.